Har­vard re­searchers hope to bridge the pro­tein gap with new in­sti­tute

Tim­o­thy Springer just un­veiled the new In­sti­tute for Pro­tein In­no­va­tion (IPI), aim­ing to bridge the gap in study­ing pro­tein ther­a­peu­tics. Springer, known for hav­ing a guid­ing hand in biotechs like Mod­er­na Ther­a­peu­tics and Ed­i­tas, kicked in $10 mil­lion from his own pock­et along­side a grant of $5 mil­lion from the Mass­a­chu­setts Life Sci­ences Cen­ter.

While the in­sti­tute will be housed for one year with­in the Har­vard Med­ical School, it will be an in­de­pen­dent en­ti­ty, col­lab­o­rat­ing with aca­d­e­mics and in­dus­try alike to ad­vance pro­tein sci­ence, which co-founder and as­sis­tant pro­fes­sor An­drew Kruse ex­plained to End­points News is “the bridge be­tween the ge­nomics dis­cov­ery, dis­cov­ery of a giv­en tar­get for in­stance and the ac­tu­al de­vel­op­ment of a ther­a­peu­tic tar­get­ing a par­tic­u­lar pro­tein.”

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN